Enzymes that Unlock
Your Next Discovery
0
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

The Largest Overlooked Cost Driver in Viral Vector Production

  • Up to half of produced vector is lost during Down Stream Processing(DSP)
  • The majority of manufacturing cost accumulates is DSP raw materials
  • Nuclease design decisions determine downstream economics

Download here and get access to the interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Investors News

ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch

May 28, 2026

Tromsø, Norway – 28 May 2026 – ArcticZymes Technologies ASA (OSE: AZT) today announced that, following approval at its Annual General Meeting, Dr. Hanna Pirita Lesch has been elected to the Company’s Board of Directors. Dr. Frank Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected as a Board member. Sharon Brownlow steps down from the Board after a period of valued service.

Read More
Read More
Q1 2026 results - Acticzymes

ArcticZymes Technologies Delivers 36% Sales Growth in Q1 2026, with Molecular Tools Rebound and Biomanufacturing Momentum

May 7, 2026

Tromsø, Norway, May 7, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported first-quarter 2026 results, with sales up 36% year-on-year to NOK 31.8 million and positive EBITDA — a NOK 5.3 million turnaround versus Q1 2025. Growth was broad-based across both business segments, with Molecular Tools rebounding sharply and Biomanufacturing extending its commercial reach among global CDMOs.

Read More
Read More

ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing

Apr 30, 2026

ArcticZymes today announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company’s strategic expansion into the rapidly growing RNA therapeutics manufacturing market.

Read More
Read More

ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing

Apr 28, 2026

ArcticZymes Technologies today announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program.

Read More
Read More